Abivax shares slip back below €76.05, in the lower ranks of the SBF 120
The Paris-based biotech specialising in inflammatory diseases moves into negative territory as the close approaches, while its benchmark index remains virtually unchanged. The stock extends a difficult quarter and remains well below its long-term reference levels.
A decline brings the stock closer to its support at €76.05
Abivax shares fell 2.4% to €77.20 intraday and are among the largest decliners in the SBF 120, which is nonetheless flat. The price is approaching its support at €76.05, a level the stock had broken on 6 November before recovering in the following sessions. Resistance is at €84.35.
The stock remains below its 20-day moving average (a gap of 3.29%) and its 200-day moving average (a gap of 21.14%), illustrating the scale of the medium-term decline: it has lost nearly 25% over three months.
Abivax is a single company listed on two exchanges, in Paris and on the Nasdaq, where the ADS reflects the same stock, at a ratio of one share per ADS.
Short positions total 5.59% of the share capital
According to the disclosures reviewed, five funds hold a combined net short position of 5.59% of the share capital, up 0.24 points over one month, after 5.35% thirty days ago. This level indicates that a significant share of institutional investors remains positioned against the stock or is seeking to hedge its exposure.
The increase over the period remains modest, which does not allow it to be read as a sudden wave of distrust. To put the trend in context, the stock has fallen 5.8% over one month and nearly 25% over three months. The €76.05 level is the closest technical reference to the current price.